Global Pharmaceutical Outfits, While Closing Discovery Centers In Japan, Are Forging Alliances With Japanese Researchers (Part 3 Of 3)
This article was originally published in PharmAsia News
Executive Summary
Several multinational pharmaceutical companies have shut down their Japan-based discovery research facilities over the last few years. Some are relying more on discovery partnerships with local drug research entities in Japan. PharmAsia News' Tokyo bureau examines the factors behind the trend in this third article in a three-part series on the subject. Part one appeared in PharmAsia News on July 13, 2009, and part two appeared on July 20.
You may also be interested in...
Kobe Biocluster Looks To Support Partners, Novel Tech
The Foundation for Biomedical Research and Innovation (FBRI) co-ordinates Kobe’s life sciences activities and heads up the Biomedical Kansai network, Japan’s largest biocluster. It is seeking international life sciences investors and partners for licensing, co-development and funding options.
Today Asia, Tomorrow The World? AstraZeneca Looks To Align R&D Strategy Across Emerging Markets
WASHINGTON - AstraZeneca PLC is looking to leverage its experience in Asia to catch up with competitors in other fast growing emerging markets like Russia and Brazil, according to Steve Yang, the company's head of R&D in Asia and emerging markets. Yang, who joined AZ in January, is based in Shanghai and reports to R&D President Martin Mackay
Today Asia, Tomorrow The World? AstraZeneca Looks To Align R&D Strategy Across Emerging Markets
WASHINGTON - AstraZeneca PLC is looking to leverage its experience in Asia to catch up with competitors in other fast growing emerging markets like Russia and Brazil, according to Steve Yang, the company's head of R&D in Asia and emerging markets. Yang, who joined AZ in January, is based in Shanghai and reports to R&D President Martin Mackay